Liver Cancer

An analysis of patients with advanced hepatocellular carcinoma and elevated AFP who received second-line Cyramza showed improved survival, according to data from the phase 3 REACH study.

Researchers need to learn more about the biology of liver cancer to develop better treatments.

Refined treatments and targeted drugs signal slow yet significant progress for liver cancer.

Patients and families face difficult decisions when the prognosis is poor, but communication and an action plan may help.

Chronic inflammation causes cancer. Find out how and what's being done about it.

Treatment updates from the 2009 ASCO Gastrointestinal Cancers Symposium.

Recent drug approvals yield a new chemotherapy agent, a first for liver cancer, a safer prevention method, and good news for a drug-resistant cancer.

Updates from the 2007 meeting of the American Society of Clinical Oncology includes news on liver, kidney, lung, colon, pancreatic and breast cancers.

The incidence of the most common type of liver cancer, known as hepatocellular carcinoma, has been on the rise in recent decades—and researchers know why.

While liver cancer is typically hard to diagnosis, and usually found in its later stages, there are ways to be proactive about screenings and know your risk.

An approval in breast cancer, positive clinical trial results in liver cancer, while a prostate cancer drug disappoints.